Merck , known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has granted MK-5172/MK-8742 Breakthrough Therapy designation for treatment of chronic hepatitis C virus infection.
http://www.freshnews.com/news/860313/merck-receives-breakthrough-therapy-designation-mk-5172-mk-8742-investigational-oral-co
http://www.freshnews.com/news/860313/merck-receives-breakthrough-therapy-designation-mk-5172-mk-8742-investigational-oral-co
No comments:
Post a Comment